SARS-CoV-2 (COVID-19) ORF7a Antibody

Contact us
ProSci
Product Code: PSI-9285
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9285-0.02mg0.02mg£150.00
Quantity:
PSI-9285-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19) ORF7a antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 2
<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) ORF7a in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) ORF7a antibody (9285, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 ORF7a protein was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
2 / 2
<strong>Figure 2 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) ORF7a Antibody, 9285. A direct ELISA was performed using SARS-CoV-2 ORF7a immunogen peptide (9285P)) as coating antigen and the anti-SARS-CoV-2 (COVID-19) ORF7a antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000 ng/mL
❮❯

<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) ORF7a in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) ORF7a antibody (9285, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 ORF7a protein was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
<strong>Figure 2 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) ORF7a Antibody, 9285. A direct ELISA was performed using SARS-CoV-2 ORF7a immunogen peptide (9285P)) as coating antigen and the anti-SARS-CoV-2 (COVID-19) ORF7a antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000 ng/mL

Documents

Further Information

Additional Names:
ORF7a protein, Accessory protein 7a, Protein U122, Protein X4, ORF7a
Application Note:
IHC: 1 μg/mL

Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) ORF7a antibody can detect 2 ng of free peptide at 1 μg/mL in ELISA. All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF7a and ORF7a. ORF7a plays a role as antagonist of host tetherin (BST2), disrupting its antiviral effect. It acts by binding to BST2 thereby interfering with its glycosylation. It may suppress small interfering RNA (siRNA) and may bind to host ITGAL, thereby playing a role in attachment or modulation of leukocytes (3).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Taylor et al. J. Virol. 2015; 89:11820-11833.
Buffer:
SARS-CoV-2 (COVID-19) ORF7a antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV ORF7a: (73%).
Immunogen:
Anti-SARS-CoV-2 (COVID-19) ORF7a antibody (9285) was raised against a peptide corresponding to 15 amino acids near the central domain of SARS-CoV-2 (COVID-19) ORF7a protein.

The immunogen is located within 40-90 amino acids of the SARS-CoV-2 (COVID-19) ORF7a protein.
NCBI Gene ID #:
43740573
NCBI Official Name:
ORF7a protein
NCBI Official Symbol:
ORF7a
NCBI Organism:
Severe acute respiratory syndrome coronavirus 2
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
14kD
Protein Accession #:
P0DTC7.1
Protein GI Number:
1835921947
Purification:
SARS-CoV-2 (COVID-19) ORF7a Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC7.1
User NOte:
Optimal dilutions for each application to be determined by the researcher.